{
    "title": "112_hr6502",
    "content": "The Act titled \"Life-Threatening Diseases Compassion through Combination Therapy Act of 2012\" promotes the development of combinations of investigational new drugs for serious diseases by providing marketing exclusivity and priority review for significant drug combinations. The Secretary may designate a combination of drugs as significant if it includes 2 or more drugs that offer the potential to advance treatment for a serious or life-threatening disease. The Secretary may designate a combination of drugs as significant if it includes at least 2 drugs that are not approved under section 505 of this Act and have the potential to advance treatment for a serious or life-threatening disease. The Secretary may designate drug combinations that are not approved under section 505 of this Act to encourage codevelopment. Task force recommendations are considered in the designation process. The Secretary can designate drug combinations for codevelopment, as per section 3(c)(1) of the Life-Threatening Diseases Compassion through Combination Therapy Act of 2012. Manufacturers can request the Secretary to determine if a combination of drugs is significant, with a response required within 30 days. The Secretary can designate drug combinations for codevelopment under the Life-Threatening Diseases Compassion through Combination Therapy Act of 2012. Manufacturers can request the Secretary to determine if a drug combination is significant, with a response within 30 days. If the combination meets requirements, the Secretary notifies the requester. The Secretary can designate drug combinations as significant under the Life-Threatening Diseases Compassion through Combination Therapy Act of 2012. If a drug combination meets the requirements, the Secretary will notify the requester. The Secretary can designate drug combinations as significant under the Life-Threatening Diseases Compassion through Combination Therapy Act of 2012. If a drug combination does not meet the requirements, the Secretary will inform the requester. Requests for designation must be made concurrently with or after submitting an application. The Secretary can designate significant drug combinations under the Life-Threatening Diseases Compassion through Combination Therapy Act of 2012. Requests for designation must be made concurrently with or after submitting an application for drug investigation, not later than the completion of phase I trials for any of the drugs involved. The Secretary must provide an initial list of significant drug combinations within 180 days of the Act's enactment. The Secretary must develop and publish an initial list of significant drug combinations under the Life-Threatening Diseases Compassion through Combination Therapy Act of 2012. This list will be updated annually to include additional drug combinations designated as significant. The Secretary updates the list of significant drug combinations annually, adding new combinations and excluding those that no longer meet the requirements. This process extends market exclusivity for approved drugs. The Secretary updates the list of significant drug combinations annually, extending market exclusivity for approved drugs by designating certain combinations. If a drug is included in a designated combination, the market exclusivity periods under various sections of the law will be extended by 6 years. The market exclusivity period for a drug in a designated significant drug combination can be extended by 6 months under certain conditions, as outlined in subsection (j)(5)(F) of section 505. This extension does not apply to certain supplements or subsequent applications related to the original application. The market exclusivity period for a drug in a designated significant drug combination can be extended by 6 months under certain conditions, as outlined in subsection (j)(5)(F) of section 505. This extension applies to subsequent applications filed by the same sponsor or manufacturer for changes that result in new indications, routes of administration, dosing schedules, or dosage forms. The Priority Review provision requires the Secretary to review and take action on any application for a drug in a significant drug combination within 6 months of receipt. This applies to changes that result in new indications, routes of administration, dosing schedules, dosage forms, delivery systems, devices, or strengths, or modifications to the drug's structure that do not affect safety or effectiveness. The Priority Review provision mandates the Secretary to review and act on drug combination applications under section 505(b) or section 351(k) within 6 months. \"Significantly advance treatment\" refers to providing treatment for life-threatening diseases without existing therapies or demonstrating clinical effectiveness when therapies are available. The drug combination must demonstrate improved effects on serious outcomes of a disease, such as superiority or minimizing drug resistance, in clinical investigations. The Fast Track Product designation under the Federal Food, Drug, and Cosmetic Act is amended to include drugs in significant drug combinations designated under section 505E(a). The Fast Track Product designation is amended to include drugs in significant drug combinations designated under section 505E(a). Additionally, a Codevelopment Task Force is established. The Secretary of Health and Human Services will establish an interagency task force within 6 months to promote codevelopment of drugs in significant combinations. The task force will include experts in research and drug development for serious diseases like cancer, with duties including recommending a list of significant drug combinations. The task force established by the Secretary of Health and Human Services will recommend a list of significant drug combinations under section 505E of the Federal Food, Drug, and Cosmetic Act. The list will be made publicly available for comments. The task force will revise the list of significant drug combinations based on public comments and submit the updated list annually to the Secretary and Congress. The task force will annually update and submit a list of significant drug combinations to the Secretary and Congress, along with a policy report identifying key details. The task force will submit a report to the Secretary and Congress identifying challenges and opportunities for codeveloping drugs in significant combinations, along with recommendations for policy changes. The task force will submit a report to the Secretary and Congress with recommendations for policy changes to support codevelopment of drugs in significant combinations. Before submitting the report, a draft will be made public for public comments. The task force will not be subject to the Federal Advisory Committee Act. A \"significant drug combination\" refers to a combination of drugs that can advance treatment for serious diseases. The task force will focus on drug combinations that can significantly advance treatment for serious diseases, meeting specific criteria for codevelopment outlined by the FDA. The combinations must include at least 2 drugs that are not yet approved or licensed under relevant regulations. The FDA task force will focus on drug combinations for serious diseases that meet specific criteria for codevelopment. The combinations must include at least 2 drugs not yet approved under relevant regulations. SEC. 4. STUDY. The Secretary of Health and Human Services will conduct a study on the impact of exclusivity extensions on drug combinations. Interim findings will be shared with a task force and the public for comments. Final findings must be provided within 5 years. The Secretary of Health and Human Services will conduct a study on the impact of exclusivity extensions on drug combinations. Final findings must be submitted to Congress within 5 years after allowing public comments."
}